AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01825798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
Study NCT01825798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
Study NCT03197168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to reduce self-stigma among people with mental illness
Description: This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.~The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively.
Study NCT03197168 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
Study NCT02932098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge instructions reminders
Description: Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge.
Study NCT02932098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompts to report symptoms via the web-enabled app
Description: Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
Study NCT02932098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Alerts
Description: Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
Study NCT02932098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Alerts
Description: Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
Study NCT03322839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategies
Description: The school-management will participate in a one-day training aimed at providing knowledge and skills related the recommendations of the guideline for the prevention of common mental disorders at the workplace.In addition every intervention school will form an implementation team that is responsible for the implementation of the guideline. The implementation team will comprise of approximately 3-5 individuals with experience in the field of social and organizational work environment, for example school-management and occupational health and safety representative. The implementation teams will participate in 4-5 workshops aimed at supporting the implementation process. Intervention schools within the same municipality will participate in the same workshop in order to promote peer-support.
Study NCT03322839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single implementation strategy
Description: The school-management will participate in a one-day training aimed at providing knowledge and skills related to the recommendations of the guideline for the prevention of common mental disorders at the workplace
Study NCT00607724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Study NCT00999999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniotomy supra- or infratentorial, dural closure
Description: After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
Study NCT00999999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy supra- or infratentorial, dural closure
Description: After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
Study NCT00852605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Non-Invasive Ventilation
Study NCT01464775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Description: Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
Study NCT01464775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard White Light Laparoscopy
Description: Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
Study NCT03551691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20mg Capsule
Description: Omeprazole 20mg daily for 28 days
Study NCT03551691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Identically-appearing capsule to omeprazole for 28 days
Study NCT03567629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
Study NCT03567629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
Study NCT02920112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone based Cognitive Behavioral Therapy
Description: 6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
Study NCT04224168 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Beans
Description: Please see arm group Green beans for description
Study NCT04224168 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Pectin
Description: Please see arm group liquid pectin for description
Study NCT00505310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing
Description: 20 minutes of writing on different topics at four different times.
Study NCT00505310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
Study NCT02775006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2
Study NCT02775006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150mg/day
Study NCT02764099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Training
Description: The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
Study NCT02758743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetium Lozenge
Description: Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
Study NCT02758743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no active substance will not have the effect on intervention device.
Study NCT00910286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Ventilator
Description: The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
Study NCT00903760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 20 mg/m\^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
Study NCT00903760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine 10 mg/m\^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
Study NCT04032834 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
Study NCT01918592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/acetate-PET imaging
Study NCT04420039 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic biliary transmural drainage
Description: Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent.
Study NCT01183390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg Tablets
Study NCT01183390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg Tablets
Study NCT03662269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: indomethacin (75mg, bid, po, 14days)
Study NCT03662269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (75mg, bid, po, 14days)
Study NCT03662269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: placebo (20mg, qd, po, 14days)
Study NCT03662269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: placebo (20mg, qd, po, 14days)
Study NCT00463905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical assessment +/- radiography
Description: Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
Study NCT00000416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation counseling
Description: Provided in 2 in-person meetings and in follow-up phone calls
Study NCT00000416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation counseling
Description: Provided in 2 in-person meetings and in follow-up phone calls
Study NCT03384303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized meal test
Description: Preoperatively and postoperatively standardized meal test
Study NCT03153150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study NCT03153150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study NCT03153150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study NCT03153150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study NCT03153150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study NCT03153150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenindione
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study NCT03153150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study NCT01452568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 150mg/daily for three months, starting day after surgery
Study NCT01452568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
Study NCT01240551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18 NaF
Description: All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
Study NCT02981927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Study NCT02567851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Monoclonal antibody drug conjugate
Study NCT00309647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
Study NCT00309647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Monovalent Whole virus (H5N1)
Description: 2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
Study NCT01638390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with the VisuMax™ Femtosecond Laser
Description: The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Study NCT03863132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR
Description: Repair of defective aortic valve by microsurgical Intervention.
Study NCT00551850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-412
Description: oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
Study NCT02432664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-108 Part I
Description: Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
Study NCT02432664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part I
Description: Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
Study NCT02432664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-108-Part II
Description: Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
Study NCT02432664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part II
Description: Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
Study NCT02432664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-108 Part III
Description: Oral capsules 1 - 4 times daily for 7 to 10 days
Study NCT02432664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
Study NCT01627535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interoperative Optical Imaging and Spectroscopy
Description: Real time processing and display of i2DOS maps in the operating arena
Study NCT00129935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT00129935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00129935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT00129935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT00129935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT00129935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT03984513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surviving and Thriving in the Real World
Description: The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
Study NCT03984513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program for the Education and Enrichment of Relational Skills
Description: Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
Study NCT02916550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
Study NCT03051399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.